Latest Investor Relations News

AMA Group Limited plans a 1-for-10 consolidation of its shares and performance rights to simplify its capital structure and reduce share price volatility, pending shareholder approval at the November 2025 AGM.

Auckland International Airport Limited confirms the share price for its Dividend Reinvestment Plan and details its ordinary and supplementary dividends for the first half of 2025.

EMVision Medical Devices has launched a Share Purchase Plan allowing shareholders to invest up to A$30,000 at $1.94 per share, sweetened by free-attaching options exercisable at $3.40 each.

EMU NL’s securities have been suspended from ASX trading due to a failure to maintain the minimum number of directors required by law. The suspension highlights governance challenges and raises questions about the company’s path to compliance.

The Star Entertainment Group has finalized a crucial covenant waiver with its syndicated lenders, easing financial pressures ahead of its FY2025 audited report. This development clarifies ongoing negotiations and sets the stage for the company’s next financial chapter.

360 Capital Mortgage REIT (ASX – TCF) has announced an off-market equal access buy-back of up to 5% of its units, offering eligible unitholders a chance to sell at a price linked to net tangible asset backing plus distributions. The buy-back opens on 8 October 2025 and closes on 27 October 2025.

Southern Palladium has responded to an ASX price query denying undisclosed information behind its recent share price rise, instead pointing to positive commodity price trends and ongoing project developments.

OncoSil Medical has affirmed the materiality of the PANCOSIL Phase 1-2 trial results and detailed its compliance with ASX disclosure rules following the data presentation at CIRSE 2025.

Altamin Limited has initiated a 45 for 100 accelerated pro-rata entitlement offer at $0.025 per share to raise up to AUD 6.46 million, supporting its Lazio and Gorno projects in Italy. The offer includes a strong institutional backing and opens to eligible retail shareholders across multiple jurisdictions.

Imagion Biosystems has completed the second tranche of its $3.5 million placement, raising $2.85 million to advance its proprietary MagSense® imaging technology targeting breast, prostate, and ovarian cancers.

TT Investments, led by 360 Capital’s Executive Chairman Tony Pitt, has launched an unconditional off-market takeover bid for 360 Capital Group at an improved price of A$0.31 per security, signaling potential delisting and operational overhaul.

Perpetual Limited has updated its dividend announcement, confirming a 10-day VWAP-based DRP price of AUD 19.03 for its unfranked interim dividend of AUD 0.54 per share payable in October 2025.